Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase.
Aldose reductase (aldehyde reductase 2) catalyses the conversion of glucose to sorbitol, and methylglyoxal to acetol. Treatment with aldose reductase inhibitors (ARIs) is a potential approach to decrease the development of diabetic complications. The sulphonylnitromethanes are a recently discovered class of aldose reductase inhibitors, first exemplified by ICI215918. We now describe enzyme kinetic characterization of a second sulphonylnitromethane, 3',5'-dimethyl-4'-nitromethylsulphonyl-2-(2-tolyl)acetanilide (ZD5522), which is at least 10-fold more potent against bovine lens aldose reductase in vitro and which also has a greater efficacy for reduction of rat nerve sorbitol levels in vivo (ED95 = 2.8 mg kg-1 for ZD5522 and 20 mg kg-1 for ICI 215918). ZD5522 follows pure noncompetitive kinetics against bovine lens aldose reductase when either glucose or methylglyoxal is varied (K(is) = K(ii) = 7.2 and 4.3 nM, respectively). This contrasts with ICI 215918 which is an uncompetitive inhibitor (K(ii) = 100 nM) of bovine lens aldose reductase when glucose is varied. Against human recombinant aldose reductase, ZD5522 displays mixed noncompetitive kinetics with respect to both substrates (K(is) = 41 nM, K(ii) = 8 nM with glucose and K(is) = 52 nM, K(ii) = 3.8 nM with methylglyoxal). This is the first report of the effects of a sulphonylnitromethane on either human aldose reductase or utilization of methylglyoxal. These results are discussed with reference to a Di Iso Ordered Bi Bi mechanism for aldose reductase, where the inhibitors compete with binding of both the aldehyde substrate and alcohol product. This model may explain why aldose reductase inhibitors follow noncompetitive or uncompetitive kinetics with respect to aldehyde substrates, and X-ray crystallography paradoxically locates an ARI within the substrate binding site. Aldehyde reductase (aldehyde reductase 1) is closely related to aldose reductase. Inhibition of bovine kidney aldehyde reductase by ZD5522 follows uncompetitive kinetics with respect to glucuronate (K(ii) = 39 nM), indicating a selectivity greater than 5-fold for bovine aldose reductase relative to aldehyde reductase.
Cook
P N
PN
ZENECA Pharmaceuticals, Macclesfield, Cheshire, U.K.
Ward
W H
WH
Petrash
J M
JM
Mirrlees
D J
DJ
Sennitt
C M
CM
Carey
F
F
Preston
J
J
Brittain
D R
DR
Tuffin
D P
DP
Howe
R
R
D000083:Acetanilides / Q000494:pharmacology*; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D002417:Cattle; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000201:enzymology; D007700:Kinetics; D007908:Lens, Crystalline / Q000201:enzymology*; D009249:NADP; D011765:Pyruvaldehyde / Q000378:metabolism; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D013450:Sulfones / Q000494:pharmacology*
D000083:Acetanilides; D011994:Recombinant Proteins; D013450:Sulfones; C090184:ZENECA ZD 5522; D009249:NADP; D011765:Pyruvaldehyde; D000449:Aldehyde Reductase; D005947:Glucose